Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779389 · ClinicalTrials.gov registry record · Phase 1
Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00779389: Completed Phase 1 study, sponsored by University of Pittsburgh.
NCT00779389 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00779389, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.
Interventions
- DRUG Placebo
- DRUG Erlotinib
- DRUG Dasatinib + Placebo
- DRUG Erlotinib plus Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT00779389 record still lists
NCT00779389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00779389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00779389 about?
NCT00779389 is a clinical study titled "Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family". The central hypothesis to be tested in this study is that dual blockade of EGFR and Src pathways or proteins are distinct compared to inhibition of either kinase alone in head and neck and lung cancers.
What is the current status of trial NCT00779389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2009-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00779389?
The interventions under investigation include: Placebo (DRUG), Erlotinib (DRUG), Dasatinib + Placebo (DRUG), Erlotinib plus Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00779389?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00779389's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia